Johnson & Johnson is normally a good buy for its dividend and the stability it offers. Over the past five years, however, the ...
Hosted on MSN1mon
Johnson & Johnson ketamine-derived nasal spray gets FDA approval for depression, but JNJ stock dips on earningsapproved Johnson & Johnson’s nasal spray, Spravato (esketamine), to treat major depressive disorder. Oral antidepressants are the most common treatment for depression, but they don’t work for ...
Johnson & Johnson, a leader in immunology, has developed ARGES, a new AI-powered tool that could transform endoscopic ...
For people with AD, Johnson & Johnson's research offers hope ... “Many patients with AD have higher rates of depression, anxiety, stress and suicide,” she says. Existing treatments for AD ...
Johnson & Johnson has a strong business, several growth opportunities, and a safe dividend. The company does face headwinds, but it should be able to overcome them. Some might describe Johnson ...
Bryan Johnson is a biohacker on a mission to conquer death and has been injecting ketamine into his system to see how it ...
Johnson & Johnson (NYSE ... Its key product, Caplyta, is an approved treatment for schizophrenia and depression related to bipolar I or II disorder. It may also soon obtain approval for major ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results